Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

Ariza, 1999, Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin, Lancet, 353, 1587, 10.1016/S0140-6736(99)01017-X Barry, 2001, In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers, Antimicrob Agents Chemother, 45, 1919, 10.1128/AAC.45.6.1919-1922.2001 Bert, 2003, Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients, J Clin Microbiol, 41, 5147, 10.1128/JCM.41.11.5147-5152.2003 Bierbaum, 1999, Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany, Eur J Clin Microbiol Infect Dis, 18, 691, 10.1007/s100960050380 Centers for Disease Control (1999). Antimicrobial Resistance 1999 NNIS ICU Report. http://www.cdc.gov/ncidod/hip/NNIS/ar_surv99.htm Chang, 2003, Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene, N Engl J Med, 348, 1342, 10.1056/NEJMoa025025 Charles, 2004, Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus, Clin Infect Dis, 38, 448, 10.1086/381093 Chesneau, 2000, Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals, J Antimicrob Chemother, 45, 887, 10.1093/jac/45.6.887 Critchley, 2003, Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001, J Antimicrob Chemother, 51, 639, 10.1093/jac/dkg130 de la Maza, 1989, In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria, Antimicrob Agents Chemother, 33, 1383, 10.1128/AAC.33.8.1383 Fridkin, 2001, Vancomycin-intermediate and -resistant Staphylococcus aureus, Clin Infect Dis, 32, 108, 10.1086/317542 Geisel, 2001, Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus, Eur J Clin Microbiol Infect Dis, 20, 685, 10.1007/s100960100595 Goldstein, 2003, In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates, Antimicrob Agents Chemother, 47, 337, 10.1128/AAC.47.1.337-341.2003 Hanberger, 1991, Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs, Antimicrob Agents Chemother, 35, 1710, 10.1128/AAC.35.9.1710 Hiramatsu, 1997, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, J Antimicrob Chemother, 40, 135, 10.1093/jac/40.1.135 Howden, 2004, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin Infect Dis, 38, 521, 10.1086/381202 Howe, 2000, Heterogeneous resistance to vancomycin in Staphylococcus aureus, J Antimicrob Chemother, 45, 130, 10.1093/jac/45.1.130 Kim, 2002, Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea, J Clin Microbiol, 40, 1376, 10.1128/JCM.40.4.1376-1380.2002 Kumon, 1989, [Pharmacokinetics of arbekacin in healthy volunteers and patients with renal insufficiency], Jpn J Antibiot, 42, 200 Lamp, 1993, Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium, Antimicrob Agents Chemother, 37, 605, 10.1128/AAC.37.3.605 Liu C, Chambers HF (2003). Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance and critical assessment of diagnostic methods Antimicrob Agents Chemother 47, 3040–3045 National Committee for Clinical Laboratory Standards (NCCLS) (2003a). Supplemental tables M100-S13. Wayne, PA National Committee for Clinical Laboratory Standards (NCCLS) (2003b). Approved standard M7-A6. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Wayne, PA Niijima, 1991, New antimicrobial agent series XL: Arbekacin, Jpn J Antibiot, 44, 705 Obayashi, 1997, Investigation of nosocomial infection caused by arbekacin-resistant, methicillin-resistant Staphylococcus aureus, Diagn Microbiol Infect Dis, 28, 53, 10.1016/S0732-8893(97)00005-9 Smith, 1999, Emergence of vancomycin resistance in Staphylococcus aureus, N Engl J Med, 340, 493, 10.1056/NEJM199902183400701 Tenover, 2004, Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania, Antimicrob Agents Chemother, 48, 275, 10.1128/AAC.48.1.275-280.2004 Watanabe, 1997, Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus, J Antimicrob Chemother, 39, 471, 10.1093/jac/39.4.471 Wise, 2001, Activity of daptomycin against Gram-positive pathogens: A comparison with other agents and the determination of a tentative breakpoint, J Antimicrob Chemother, 48, 563, 10.1093/jac/48.4.563 Wise, 2002, Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers, Antimicrob Agents Chemother, 46, 31, 10.1128/AAC.46.1.31-33.2002